When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new ...

Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Moderna has announced FDA approval for its new COVID-19 vaccine, mNexspike (mRNA-1283). This next-generation shot targets a ...

As of today, the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended ...